Source link : https://newshealth.biz/health-news/vepdegestrant-earns-fda-nod-for-esr1-mutated-breast-cancer/
Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease. Medscape Medical News Source link : https://www.medscape.com/viewarticle/vepdegestrant-earns-fda-nod-esr1-mutated-breast-cancer-2026a1000e23?src=rss Author : Publish date : 2026-05-01 20:14:00 Copyright for syndicated content belongs to the linked Source.
The post Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-01 20:14:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8